{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:58:42Z","timestamp":1782417522147,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pompe disease is caused by mutations in the <jats:italic>GAA<\/jats:italic> gene, resulting in deficient lysosomal acid-\u03b1-glucosidase activity in patients, and a progressive decline in mobility and respiratory function. Enzyme replacement therapy is one therapeutic option, but since not all patients respond to this treatment, alternative interventions should be considered. One <jats:italic>GAA<\/jats:italic> mutation, c.-32-13T\u2009&gt;\u2009G, impacts upon normal exon 2 splicing and is found in two-thirds of late-onset cases. We and others have explored a therapeutic strategy using splice modulating phosphorodiamidate morpholino oligomers to enhance <jats:italic>GAA<\/jats:italic> exon 2 inclusion in the mature mRNA of patients with one c.-32-13T\u2009&gt;\u2009G allele. We designed 20 oligomers and treated fibroblasts derived from five patients to identify an oligomer sequence that maximally increased enzyme activity in all fibroblasts. The most effective splice correcting oligomer was chosen to treat forced-myogenic cells, derived from fibroblasts from nine patients carrying the c.-32-13T &gt;\u2009G mutation. After transfection, we show increased levels of the full-length <jats:italic>GAA<\/jats:italic> transcript, acid-\u03b1-glucosidase protein, and enzyme activity in all patients\u2019 myogenic cells, regardless of the nature of the mutation in the other allele. This data encourages the initiation of clinical trials to assess the therapeutic efficacy of this oligomer for those patients carrying the c.-32-13T\u2009&gt;\u2009G mutation.<\/jats:p>","DOI":"10.1038\/s41598-020-63461-2","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T10:04:37Z","timestamp":1587463477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease"],"prefix":"10.1038","volume":"10","author":[{"given":"May Thandar","family":"Aung-Htut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Tchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve D.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"63461_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJM199506013322204","volume":"332","author":"M Chillon","year":"1995","unstructured":"Chillon, M. et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N. Engl. J. Med. 332, 1475\u20131480, https:\/\/doi.org\/10.1056\/NEJM199506013322204 (1995).","journal-title":"N. Engl. J. Med."},{"key":"63461_CR2","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1073\/pnas.78.4.2455","volume":"78","author":"RA Spritz","year":"1981","unstructured":"Spritz, R. A. et al. Base substitution in an intervening sequence of a beta+-thalassemic hu man globin gene. Pro.c Natl. Acad. Sci. USA 78, 2455\u20132459 (1981).","journal-title":"Pro.c Natl. Acad. Sci. USA"},{"key":"63461_CR3","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N Engl J Med 381, 1644\u20131652, https:\/\/doi.org\/10.1056\/NEJMoa1813279 (2019).","journal-title":"N Engl J Med"},{"key":"63461_CR4","unstructured":"FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation, Available online, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation (2019)."},{"key":"63461_CR5","unstructured":"FDA grants accelerated approval to first drug for Duchenne muscular dystrophy [(accessed on 19 September 2016], Available online, http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm (2016)."},{"key":"63461_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","volume":"8","author":"EW Ottesen","year":"2017","unstructured":"Ottesen, E. W. ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy. Transl. Neurosci. 8, 1\u20136, https:\/\/doi.org\/10.1515\/tnsci-2017-0001 (2017).","journal-title":"Transl. Neurosci."},{"key":"63461_CR7","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/hmg\/3.7.1081","volume":"3","author":"ML Huie","year":"1994","unstructured":"Huie, M. L. et al. Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-\u2009>\u2009G) mutation in a majority of patients and a novel IVS10 (+1GT->CT) mutation. Hum. Mol. Genet. 3, 2231\u20132236 (1994).","journal-title":"Hum. Mol. Genet."},{"key":"63461_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ebiom.2019.03.048","volume":"43","author":"AJ Bergsma","year":"2019","unstructured":"Bergsma, A. J. et al. A genetic modifier of symptom onset in Pompe disease. EBioMedicine 43, 553\u2013561, https:\/\/doi.org\/10.1016\/j.ebiom.2019.03.048 (2019).","journal-title":"EBioMedicine"},{"key":"63461_CR9","first-page":"887","volume":"56","author":"CF Boerkoel","year":"1995","unstructured":"Boerkoel, C. F. et al. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am. J. Hum. Genet. 56, 887\u2013897 (1995).","journal-title":"Am. J. Hum. Genet."},{"key":"63461_CR10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/hmg\/5.7.995","volume":"5","author":"N Raben","year":"1996","unstructured":"Raben, N., Nichols, R. C., Martiniuk, F. & Plotz, P. H. A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II). Hum. Mol. Genet. 5, 995\u20131000 (1996).","journal-title":"Hum. Mol. Genet."},{"key":"63461_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1212\/WNL.27.2.178","volume":"27","author":"M Mehler","year":"1977","unstructured":"Mehler, M. & DiMauro, S. Residual acid maltase activity in late-onset acid maltase deficiency. Neurology 27, 178\u2013184 (1977).","journal-title":"Neurology"},{"key":"63461_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cccn.2005.05.025","volume":"361","author":"K Umapathysivam","year":"2005","unstructured":"Umapathysivam, K., Hopwood, J. J. & Meikle, P. J. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease. Clin. Chim. Acta. 361, 191\u2013198, https:\/\/doi.org\/10.1016\/j.cccn.2005.05.025 (2005).","journal-title":"Clin. Chim. Acta."},{"key":"63461_CR13","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg, A. T. & Reuser, A. J. Pompe\u2019s disease. Lancet 372, 1342\u20131353, https:\/\/doi.org\/10.1016\/S0140-6736(08)61555-X (2008).","journal-title":"Lancet"},{"key":"63461_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mus.22329","volume":"45","author":"EJ Cupler","year":"2012","unstructured":"Cupler, E. J. et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 45, 319\u2013333, https:\/\/doi.org\/10.1002\/mus.22329 (2012).","journal-title":"Muscle Nerve"},{"key":"63461_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","volume":"117","author":"KM Stepien","year":"2016","unstructured":"Stepien, K. M., Hendriksz, C. J., Roberts, M. & Sharma, R. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years. Mol. Genet. Metab. 117, 413\u2013418, https:\/\/doi.org\/10.1016\/j.ymgme.2016.01.013 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"63461_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser, B. et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J. Neurol. 264, 621\u2013630, https:\/\/doi.org\/10.1007\/s00415-016-8219-8 (2017).","journal-title":"J. Neurol."},{"key":"63461_CR17","doi-asserted-by":"publisher","unstructured":"Lachmann, R. H. Treating Lysosomal Storage Disorders: What Have We Learnt? J Inherit Metab Dis, https:\/\/doi.org\/10.1002\/jimd.12131 (2019).","DOI":"10.1002\/jimd.12131"},{"key":"63461_CR18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1021\/bc1005416","volume":"22","author":"Q Zhou","year":"2011","unstructured":"Zhou, Q. et al. Strategies for Neoglycan conjugation to human acid alpha-glucosidase. Bioconjug Chem 22, 741\u2013751, https:\/\/doi.org\/10.1021\/bc1005416 (2011).","journal-title":"Bioconjug Chem"},{"key":"63461_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"LDM Pena","year":"2019","unstructured":"Pena, L. D. M. et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naive and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul Disord 29, 167\u2013186, https:\/\/doi.org\/10.1016\/j.nmd.2018.12.004 (2019).","journal-title":"Neuromuscul Disord"},{"key":"63461_CR20","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1089\/hum.2012.250","volume":"24","author":"BK Smith","year":"2013","unstructured":"Smith, B. K. et al. Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum. Gene Ther. 24, 630\u2013640, https:\/\/doi.org\/10.1089\/hum.2012.250 (2013).","journal-title":"Hum. Gene Ther."},{"key":"63461_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.21037\/atm.2019.04.67","volume":"7","author":"G Ronzitti","year":"2019","unstructured":"Ronzitti, G., Collaud, F., Laforet, P. & Mingozzi, F. Progress and challenges of gene therapy for Pompe disease. Ann Transl Med 7, 287, https:\/\/doi.org\/10.21037\/atm.2019.04.67 (2019).","journal-title":"Ann Transl Med"},{"key":"63461_CR22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/hum.2006.061","volume":"18","author":"V Arechavala-Gomeza","year":"2007","unstructured":"Arechavala-Gomeza, V. et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 18, 798\u2013810, https:\/\/doi.org\/10.1089\/hum.2006.061 (2007).","journal-title":"Hum Gene Ther"},{"key":"63461_CR23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/hum.2012.211","volume":"24","author":"H Zhou","year":"2013","unstructured":"Zhou, H. et al. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum Gene Ther 24, 331\u2013342, https:\/\/doi.org\/10.1089\/hum.2012.211 (2013).","journal-title":"Hum Gene Ther"},{"key":"63461_CR24","doi-asserted-by":"publisher","first-page":"e62114","DOI":"10.1371\/journal.pone.0062114","volume":"8","author":"C Mitrpant","year":"2013","unstructured":"Mitrpant, C. et al. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS One 8, e62114, https:\/\/doi.org\/10.1371\/journal.pone.0062114 (2013).","journal-title":"PLoS One"},{"key":"63461_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.omtn.2017.03.001","volume":"7","author":"E van der Wal","year":"2017","unstructured":"van der Wal, E., Bergsma, A. J., Pijnenburg, J. M., van der Ploeg, A. T. & Pijnappel, W. P. Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease. Mol. Ther. Nucleic Acids 7, 90\u2013100 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"63461_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.omtn.2017.03.002","volume":"7","author":"E van der Wal","year":"2017","unstructured":"van der Wal, E. et al. GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells. Mol. Ther. Nucleic Acids 7, 101\u2013115 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"63461_CR27","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ymthe.2017.05.019","volume":"25","author":"E Goina","year":"2017","unstructured":"Goina, E., Peruzzo, P., Bembi, B., Dardis, A. & Buratti, E. Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology. Mol. Ther. 25, 2117\u20132128, https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.019 (2017).","journal-title":"Mol. Ther."},{"key":"63461_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell, J. R. et al. Eteplirsen for the Treatment of Duchenne Muscular Dystrophy. Annals. of Neurology 74, 637\u2013647, https:\/\/doi.org\/10.1002\/ana.23982 (2013).","journal-title":"Annals. of Neurology"},{"key":"63461_CR29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.nmd.2013.06.581","volume":"23","author":"JR Mendell","year":"2013","unstructured":"Mendell, J. R. et al. Results at 2 years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD. Neuromuscular Disord. 23, 804\u2013805, https:\/\/doi.org\/10.1016\/j.nmd.2013.06.581 (2013).","journal-title":"Neuromuscular Disord."},{"key":"63461_CR30","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/bioinformatics\/btp124","volume":"25","author":"F Piva","year":"2009","unstructured":"Piva, F., Giulietti, M., Nocchi, L. & Principato, G. SpliceAid: a database of experimental RNA target motifs bound by splicing proteins in humans. Bioinformatics 25, 1211\u20131213, https:\/\/doi.org\/10.1093\/bioinformatics\/btp124 (2009).","journal-title":"Bioinformatics"},{"key":"63461_CR31","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1172\/JCI1505","volume":"101","author":"L Lattanzi","year":"1998","unstructured":"Lattanzi, L. et al. High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J. Clin. Invest. 101, 2119\u20132128, https:\/\/doi.org\/10.1172\/JCI1505 (1998).","journal-title":"J. Clin. Invest."},{"key":"63461_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ymgme.2007.07.006","volume":"92","author":"ME McCready","year":"2007","unstructured":"McCready, M. E. et al. Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II. Mol Genet Metab 92, 325\u2013335, https:\/\/doi.org\/10.1016\/j.ymgme.2007.07.006 (2007).","journal-title":"Mol Genet Metab"},{"key":"63461_CR33","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.1002\/humu.20745","volume":"29","author":"M Kroos","year":"2008","unstructured":"Kroos, M. et al. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 29, E13\u201326, https:\/\/doi.org\/10.1002\/humu.20745 (2008).","journal-title":"Hum Mutat"},{"issue":"Suppl 2","key":"63461_CR34","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.1007\/s10545-008-0820-2","volume":"31","author":"PR Joshi","year":"2008","unstructured":"Joshi, P. R. et al. Molecular diagnosis of German patients with late-onset glycogen storage disease type II. J Inherit Metab Dis 31(Suppl 2), S261\u2013265, https:\/\/doi.org\/10.1007\/s10545-008-0820-2 (2008).","journal-title":"J Inherit Metab Dis"},{"key":"63461_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/humu.10286","volume":"23","author":"MM Hermans","year":"2004","unstructured":"Hermans, M. M. et al. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 23, 47\u201356, https:\/\/doi.org\/10.1002\/humu.10286 (2004).","journal-title":"Hum Mutat"},{"key":"63461_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1399-0004.1996.tb03801.x","volume":"49","author":"MG Ausems","year":"1996","unstructured":"Ausems, M. G. et al. Homozygous deletion of exon 18 leads to degradation of the lysosomal alpha-glucosidase precursor and to the infantile form of glycogen storage disease type II. Clin. Genet. 49, 325\u2013328 (1996).","journal-title":"Clin. Genet."},{"key":"63461_CR37","first-page":"635","volume":"49","author":"N Zhong","year":"1991","unstructured":"Zhong, N., Martiniuk, F., Tzall, S. & Hirschhorn, R. Identification of a missense mutation in one allele of a patient with Pompe disease, and use of endonuclease digestion of PCR-amplified RNA to demonstrate lack of mRNA expression from the second allele. Am J Hum Genet 49, 635\u2013645 (1991).","journal-title":"Am J Hum Genet"},{"key":"63461_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"AWGoMoP Disease","year":"2006","unstructured":"Disease, A. W. Go. MoP. et al. Pompe disease diagnosis and management guideline. Genet Med 8, 267\u2013288, https:\/\/doi.org\/10.1097\/01.gim.0000218152.87434.f3 (2006).","journal-title":"Genet Med"},{"key":"63461_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nmd.2006.09.004","volume":"17","author":"RE Palmer","year":"2007","unstructured":"Palmer, R. E. et al. Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations. Neuromuscul Disord 17, 16\u201322, https:\/\/doi.org\/10.1016\/j.nmd.2006.09.004 (2007).","journal-title":"Neuromuscul Disord"},{"key":"63461_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pediatrneurol.2016.04.006","volume":"61","author":"QL Wang","year":"2016","unstructured":"Wang, Q. L. et al. Phenotypes and Genotypes in Five Children with Congenital Insensitivity to Pain with Anhidrosis. Pediatr Neurol 61, 63\u201369, https:\/\/doi.org\/10.1016\/j.pediatrneurol.2016.04.006 (2016).","journal-title":"Pediatr Neurol"},{"key":"63461_CR41","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/mtna.2012.30","volume":"1","author":"C Betts","year":"2012","unstructured":"Betts, C. et al. Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol. Ther. Nucleic Acids 1, e38, https:\/\/doi.org\/10.1038\/mtna.2012.30 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"63461_CR42","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond, S. M. et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 113, 10962\u201310967, https:\/\/doi.org\/10.1073\/pnas.1605731113 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"63461_CR43","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/sj.gt.3302800","volume":"13","author":"G McClorey","year":"2006","unstructured":"McClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S. & Wilton, S. D. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 13, 1373\u20131381, https:\/\/doi.org\/10.1038\/sj.gt.3302800 (2006).","journal-title":"Gene Ther."},{"key":"63461_CR44","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1021\/bc034221g","volume":"15","author":"HM Moulton","year":"2004","unstructured":"Moulton, H. M., Nelson, M. H., Hatlevig, S. A., Reddy, M. T. & Iversen, P. L. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 15, 290\u2013299, https:\/\/doi.org\/10.1021\/bc034221g (2004).","journal-title":"Bioconjug Chem"},{"key":"63461_CR45","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.nmd.2006.05.017","volume":"16","author":"G McClorey","year":"2006","unstructured":"McClorey, G. et al. Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 16, 583\u2013590, https:\/\/doi.org\/10.1016\/j.nmd.2006.05.017 (2006).","journal-title":"Neuromuscul Disord"},{"key":"63461_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/nat.2015.0550","volume":"25","author":"N Subramanian","year":"2015","unstructured":"Subramanian, N., Kanwar, J. R., Kanwar, R. K. & Krishnakumar, S. Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras. Nucleic Acid Ther. 25, 317\u2013322, https:\/\/doi.org\/10.1089\/nat.2015.0550 (2015).","journal-title":"Nucleic Acid Ther."},{"key":"63461_CR47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/nat.2013.0450","volume":"24","author":"MS Falzarano","year":"2014","unstructured":"Falzarano, M. S., Passarelli, C. & Ferlini, A. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther. 24, 87\u2013100, https:\/\/doi.org\/10.1089\/nat.2013.0450 (2014).","journal-title":"Nucleic Acid Ther."},{"key":"63461_CR48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","volume":"6","author":"RM Hudziak","year":"1996","unstructured":"Hudziak, R. M. et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 6, 267\u2013272, https:\/\/doi.org\/10.1089\/oli.1.1996.6.267 (1996).","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"63461_CR49","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/bc070060v","volume":"18","author":"A Amantana","year":"2007","unstructured":"Amantana, A. et al. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 18, 1325\u20131331, https:\/\/doi.org\/10.1021\/bc070060v (2007).","journal-title":"Bioconjug. Chem."},{"key":"63461_CR50","first-page":"202","volume":"30","author":"G Limongelli","year":"2011","unstructured":"Limongelli, G. & Fratta, F. S1.4 Cardiovascular involvement in Pompe disease. Acta Myol 30, 202\u2013203 (2011).","journal-title":"Acta Myol"},{"key":"63461_CR51","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s13760-016-0738-7","volume":"117","author":"CE Bekircan-Kurt","year":"2017","unstructured":"Bekircan-Kurt, C. E. et al. New mutations and genotype-phenotype correlation in late-onset Pompe patients. Acta Neurol Belg 117, 269\u2013275, https:\/\/doi.org\/10.1007\/s13760-016-0738-7 (2017).","journal-title":"Acta Neurol Belg"},{"key":"63461_CR52","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/gt.2016.53","volume":"23","author":"DP Rastall","year":"2016","unstructured":"Rastall, D. P. et al. Long-term, high-level hepatic secretion of acid alpha-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus. Gene. Ther. 23, 743\u2013752, https:\/\/doi.org\/10.1038\/gt.2016.53 (2016).","journal-title":"Gene. Ther."},{"key":"63461_CR53","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","volume":"4","author":"SO Han","year":"2017","unstructured":"Han, S. O. et al. Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction. Mol. Ther. Methods Clin. Dev. 4, 126\u2013136, https:\/\/doi.org\/10.1016\/j.omtm.2016.12.010 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"63461_CR54","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/hmg\/10.19.2039","volume":"10","author":"N Raben","year":"2001","unstructured":"Raben, N. et al. Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum. Mol. Genet. 10, 2039\u20132047 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"63461_CR55","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/gt.2016.53","volume":"23","author":"DP Rastall","year":"2016","unstructured":"Rastall, D. P. et al. Long-term, high-level hepatic secretion of acid alpha-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus. Gene Ther. 23, 743\u2013752, https:\/\/doi.org\/10.1038\/gt.2016.53 (2016).","journal-title":"Gene Ther."},{"key":"63461_CR56","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","volume":"8","author":"M Kinali","year":"2009","unstructured":"Kinali, M. et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918\u2013928, https:\/\/doi.org\/10.1016\/S1474-4422(09)70211-X (2009).","journal-title":"Lancet Neurol."},{"key":"63461_CR57","doi-asserted-by":"publisher","first-page":"e111079","DOI":"10.1371\/journal.pone.0111079","volume":"9","author":"L Cao","year":"2014","unstructured":"Cao, L., Han, G., Gu, B. & Yin, H. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy. PLoS One 9, e111079, https:\/\/doi.org\/10.1371\/journal.pone.0111079 (2014).","journal-title":"PLoS One"},{"key":"63461_CR58","doi-asserted-by":"publisher","unstructured":"Aung-Htut, M. T., Ham, K. A., Tchan, M. C., Fletcher, S. & Wilton, S. D. Novel Mutations Found in Individuals with Adult-Onset Pompe Disease. Genes (Basel) 11, https:\/\/doi.org\/10.3390\/genes11020135 (2020).","DOI":"10.3390\/genes11020135"},{"key":"63461_CR59","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s0022-2836(05)80360-2","volume":"215","author":"SF Altschul","year":"1990","unstructured":"Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J Mol Biol 215, 403\u2013410, https:\/\/doi.org\/10.1016\/s0022-2836(05)80360-2 (1990).","journal-title":"J Mol Biol"},{"key":"63461_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-017-1949-5","volume":"18","author":"MT Ganger","year":"2017","unstructured":"Ganger, M. T., Dietz, G. D. & Ewing, S. J. A common base method for analysis of qPCR data and the application of simple blocking in qPCR experiments. BMC Bioinformatics 18, 534, https:\/\/doi.org\/10.1186\/s12859-017-1949-5 (2017).","journal-title":"BMC Bioinformatics"},{"key":"63461_CR61","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ymgme.2012.09.010","volume":"107","author":"MI Nilsson","year":"2012","unstructured":"Nilsson, M. I. et al. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Mol. Genet. Metab. 107, 469\u2013479, https:\/\/doi.org\/10.1016\/j.ymgme.2012.09.010 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"63461_CR62","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/cbf.2838","volume":"30","author":"L Chen","year":"2012","unstructured":"Chen, L. et al. HSCs play a distinct role in different phases of oval cell-mediated liver regeneration. Cell Biochem Funct 30, 588\u2013596, https:\/\/doi.org\/10.1002\/cbf.2838 (2012).","journal-title":"Cell Biochem Funct"},{"key":"63461_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10901-x","volume":"10","author":"J Hsu","year":"2019","unstructured":"Hsu, J. et al. E2F4 regulates transcriptional activation in mouse embryonic stem cells independently of the RB family. Nat Commun 10, 2939, https:\/\/doi.org\/10.1038\/s41467-019-10901-x (2019).","journal-title":"Nat Commun"},{"key":"63461_CR64","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1091\/mbc.E11-06-0582","volume":"22","author":"TM Bunnell","year":"2011","unstructured":"Bunnell, T. M., Burbach, B. J., Shimizu, Y. & Ervasti, J. M. Beta-Actin specifically controls cell growth, migration, and the G-actin pool. Mol Biol Cell 22, 4047\u20134058, https:\/\/doi.org\/10.1091\/mbc.E11-06-0582 (2011).","journal-title":"Mol Biol Cell"},{"key":"63461_CR65","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671\u2013675, https:\/\/doi.org\/10.1038\/nmeth.2089 (2012).","journal-title":"Nat Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63461-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63461-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63461-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:40:35Z","timestamp":1670319635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63461-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63461"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63461-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"6 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.F. and S.D.W. are consultants for Sarepta Therapeutics, and M.T.A.-H. and K.A.H\u2019s salaries are partly supported by Sarepta Therapeutics. S.F. and S.D.W. are named inventors or contributors on a patent describing the correction of abnormal GAA splicing arising from the c.-32-13T\u2009>\u2009G variant. F.J.S. is an employee of Sarepta Therapeutics. M.T. and R.J. do not have any conflicting interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6702"}}